BIOAQ BioAmber

DEADLINE ALERT: Brower Piven Alerts Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Those with Losses in Excess of $100,000 from Investment in BioAmber Inc. to Contact the Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of purchasers of BioAmber Inc. (NYSE: BIOA) (BioAmber or the “Company”) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017 and/or on the open market from January 23, 2017 through March 16, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until May 17, 2017 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in BioAmber during the class period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 and the Securities Act of 1933 by virtue of the defendants’ failure to disclose during the Class Period, and in connection with its secondary public offering (“SPO”) of Company shares on or about January 23, 2017, that a large customer of BioAmber that was expected to purchase $2.8 million of succinic acid in Q4 2016 experienced a technical problem in its manufacturing facility and postponed the order to 2017.

According to the complaint, following a March 16, 2017 Company announcement of disappointing financial results and of the postponed order for succinic acid, the value of BioAmber shares declined significantly.

If you have suffered a loss in excess of $100,000 from investment in BioAmber during the class period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.

EN
09/05/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioAmber

Six Directors bought 219,998 shares at 0.750USD.

Six Directors at Bioamber Inc bought 219,998 shares at 0.750USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

 PRESS RELEASE

DEADLINE ALERT: Brower Piven Alerts Shareholders of Approaching Deadli...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of purchasers of BioAmber Inc. (NYSE: BIOA) (BioAmber or the “Company”) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017 and/or on the open market from January 23, 2017 through March 16, 2017, inclusive (the “Class Period”). Investors who w...

 PRESS RELEASE

BIOA Investors: GPM Reminds Investors of the May 17 Deadline in the Cl...

LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the May 17, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased BioAmber Inc. (“BioAmber” or the “Company”) (NYSE: BIOA) securities (1) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017 (the “Offering”); and/or (2) between January 23, 2017 and March 16, 2017, inclusive (the “Class Period”). BioAmber investors have until May 17, 2017 t...

 PRESS RELEASE

The Law Offices of Howard G. Smith Announces the Filing of a Securitie...

BENSALEM, Pa.--(BUSINESS WIRE)-- Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased BioAmber Inc. (“BioAmber” or the “Company”) (NYSE: BIOA) securities (1) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017 (the “Offering”); and/or (2) between January 23, 2017 and March 16, 2017, inclusive (the “Class Period”). BioAmber investors have until May 17, 2017 to file a lead plaintiff motion. Investors suffering l...

 PRESS RELEASE

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses I...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of purchasers of BioAmber Inc. (NYSE: BIOA) (BioAmber or the “Company”) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017 and/or on the open market from January 23, 2017 through March 16, 2017, inclusive (the “Class Period”). Investors who w...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch